Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SCHERING-PLOUGH U.S. SALES FORCE HAS REACHED 1,200 REPS

Executive Summary

SCHERING-PLOUGH U.S. SALES FORCE HAS REACHED 1,200 REPS, Senior VP-Investor Relations Ralph Golby told a March 9 health care conference in Boston sponsored by the Cowen & Company investment firm. "In response to market changes, we have increased the size of our U.S. prescription sales force to more than 1,200 and are targeting them at specific therapeutic areas and markets," Golby said. In addition to salesmen targeted at GPs and the larger hospital and cardiovascular markets, Schering has several sales groups devoted to small, contained markets including the allergy market, dermatologicals, and the cancer area. The total of 1,200 sales reps represents a near 50% increase in the last 20 months. Schering reported the size of its sales force at 800 reps in July 1986. Approximately 200 salesmen joined the company following the acquisition of Key Pharmaceuticals in the fall of 1986. Schering plans to extend the Key product line in 1988 with the once-a-day theophylline product Uni-Dur, for which an ANDA was filed in September 1987. "The compound is not affected by food consumption and is the first real 24-hour theophylline," Exec VP-Pharmaceutical Operations Donald Conklin stated. Another Schering product nearing the end of the FDA review process is the nonsedating antihistamine Claritin (loratidine), which was recommended for approval by an FDA advisory committee last fall. The company plans to follow up the one-a-day product drug with a decongestant combo. An NDA for the psuedoephedrine/loratidine product, which will compete with Merrell Dow Seldane D, was filed in March 1987. Also in the anti-allergy area, a ragweed allergen compound is currently under FDA review, Conklin noted. In addition, Schering indicated a commitment to grow its hospital business with new antibiotics now in the pipeline. A new aminoglycoside antibiotic, isepamicin, is scheduled for launch in Japan later this year. "This broad-spectrum product is active against bacteria that can resist both amikacin and our second-generation aminoglycoside, netilmicin," Conklin said. He noted that a third-generation cephalosporin licensed from Shionogi, ceftibuten, is in Phase II clinicals in the U.S. for upper and lower respiratory tract infections. Schering said it will file an NDA in 1989.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel